PROMIS NEUROSCIENCES INC
PMN · NASDAQ
Updated at 2026-10-13 15:28:33
- Today's High
- $9.48
- Today’s Low
- $8.91
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $9.61
- Previous Close
- $9.45
- Volume
- 23.72K
- Market Cap
- $84.74M
- P/E Ratio
- --
- EPS
- $-12.61
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 1920 YONGE STREET, TORONTO, ON, CANADA, M4S 3E2
- Country
- CA
- Listing Date
- 2017-04-03
- Fiscal Year End
- December
- Shares Outstanding
- 8.97M
- CIK
- 0001374339
- Website
- www.promisneurosciences.com
ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS specializes in the identification and targeting of misfolded proteins associated with these diseases, which enhances the safety and efficacy of its drug candidates. The company boasts a robust and diverse pipeline of candidates in various stages of development, positioning it favorably to address significant unmet medical needs in the biopharmaceutical arena, making it a compelling investment opportunity for institutional investors seeking growth in the healthcare sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$12.26M
2026-03-31
$8.64M
2025-12-31
$10.77M
2025-09-30
$11.75M
Net Income
2026-06-30
-$11.72M
2026-03-31
-$8.24M
2025-12-31
-$10.67M
2025-09-30
-$11.58M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-1.28
2026-03-31
$-1.26
2025-12-31
$-30.05
2025-09-30
$-8.40
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$11.72M
2026-03-31
-$8.64M
2025-12-31
-$10.77M
2025-09-30
-$11.58M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $12.26M | $8.64M | $10.77M | $11.75M |
| Net Income | -$11.72M | -$8.24M | -$10.67M | -$11.58M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-1.28 | $-1.26 | $-30.05 | $-8.40 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$11.72M | -$8.64M | -$10.77M | -$11.58M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.